Post Profile






Novartis posts a win, Roche a flop in skin cancer trials

ZURICH/MADRID (Reuters) - Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient gro...
read more

share

Related Posts


Novartis drug Zykadia gets positive trial results

Health : Reuters: Health

ZURICH (Reuters) - Novartis cancer drug Zykadia showed positive results in a phase III clinical trial in treating patients with a form of lung cancer, the Swiss drugmaker said on Friday.

Roche's Alecensa notches trial win against Pfizer's Xalkori

Health : Reuters: Health

ZURICH (Reuters) - Roche's Alecensa kept people with a specific lung cancer alive longer without their disease progressing than Pfizer's Xalkori, the Swiss drugmaker said on Monday, as it seeks to move in on the U.S. company's share...

Roche's Tecentriq fails trial in advanced bladder cancer

Health : Reuters: Health

ZURICH (Reuters) - Roche's Tecentriq drug has failed a late-stage trial in people with previously treated advanced bladder cancer, the Swiss drugmaker said on Wednesday.

Roche bid for Avastin follow-on suffers blow with trial failure

Health : Reuters: Health

ZURICH (Reuters) - Swiss drugmaker Roche's bid to follow its blockbuster cancer drug Avastin with a newer, better drug took a hit when it announced on Thursday that an investigational therapy had failed in a study against metastatic...

Bristol's drug cocktail cuts kidney cancer death risk 37 percent

Health : Reuters: Health

MADRID (Reuters) - A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday.

Comments


Copyright © 2016 Regator, LLC